Tonix Eyes August 15, 2025, for FDA Decision on TNX-102 SL for Fibromyalgia

 Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025

TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA

Fibromyalgia affects more than 10 million adults in the U.S., who are mostly women

https://www.globenewswire.com/news-release/2024/12/23/3001194/28908/en/Tonix-Pharmaceuticals-Announces-PDUFA-Goal-Date-of-August-15-2025-for-FDA-Decision-on-U-S-Marketing-Approval-for-TNX-102-SL-for-Fibromyalgia.html